These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

96 related articles for article (PubMed ID: 7710270)

  • 1. HIV proteinase inhibitors containing 2-aminobenzylstatine as a novel scissile bond replacement: biochemical and pharmacological characterization.
    Billich A; Charpiot B; Fricker G; Gstach H; Lehr P; Peichl P; Scholz D; Rosenwirth B
    Antiviral Res; 1994 Dec; 25(3-4):215-33. PubMed ID: 7710270
    [TBL] [Abstract][Full Text] [Related]  

  • 2. SDZ PRI 053, an orally bioavailable human immunodeficiency virus type 1 proteinase inhibitor containing the 2-aminobenzylstatine moiety.
    Billich A; Fricker G; Müller I; Donatsch P; Ettmayer P; Gstach H; Lehr P; Peichl P; Scholz D; Rosenwirth B
    Antimicrob Agents Chemother; 1995 Jul; 39(7):1406-13. PubMed ID: 7492076
    [TBL] [Abstract][Full Text] [Related]  

  • 3. CGP 53437, an orally bioavailable inhibitor of human immunodeficiency virus type 1 protease with potent antiviral activity.
    Alteri E; Bold G; Cozens R; Faessler A; Klimkait T; Lang M; Lazdins J; Poncioni B; Roesel JL; Schneider P
    Antimicrob Agents Chemother; 1993 Oct; 37(10):2087-92. PubMed ID: 8257128
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Aza-peptide analogs as potent human immunodeficiency virus type-1 protease inhibitors with oral bioavailability.
    Fässler A; Bold G; Capraro HG; Cozens R; Mestan J; Poncioni B; Rösel J; Tintelnot-Blomley M; Lang M
    J Med Chem; 1996 Aug; 39(16):3203-16. PubMed ID: 8759643
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Design of orally bioavailable, symmetry-based inhibitors of HIV protease.
    Kempf DJ; Marsh KC; Fino LC; Bryant P; Craig-Kennard A; Sham HL; Zhao C; Vasavanonda S; Kohlbrenner WE; Wideburg NE
    Bioorg Med Chem; 1994 Sep; 2(9):847-58. PubMed ID: 7712122
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Structure-activity relationships of HIV-1 PR inhibitors containing AHPBA.
    Sakurai M; Higashida S; Sugano M; Komai T; Yagi R; Ozawa Y; Handa H; Nishigaki T; Yabe Y
    Bioorg Med Chem; 1994 Aug; 2(8):807-25. PubMed ID: 7894975
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Nonpeptidic potent HIV-1 protease inhibitors: (4-hydroxy-6-phenyl-2-oxo-2H- pyran-3-yl)thiomethanes that span P1-P2' subsites in a unique mode of active site binding.
    Prasad JV; Para KS; Tummino PJ; Ferguson D; McQuade TJ; Lunney EA; Rapundalo ST; Batley BL; Hingorani G; Domagala JM
    J Med Chem; 1995 Mar; 38(6):898-905. PubMed ID: 7699705
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Structure-activity relationship of HIV-1 protease inhibitors containing AHPBA. Part III: Modification of P2 site.
    Takashiro E; Watanabe T; Nitta T; Kasuya A; Miyamoto S; Ozawa Y; Yagi R; Nishigaki T; Shibayama T; Nakagawa A; Iwamoto A; Yabe Y
    Bioorg Med Chem; 1998 May; 6(5):595-604. PubMed ID: 9629473
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Paracyclophanes: a novel class of water-soluble inhibitors of HIV proteinase.
    Ettmayer P; Billich A; Hecht P; Rosenwirth B; Gstach H
    J Med Chem; 1996 Aug; 39(17):3291-9. PubMed ID: 8765512
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Structure-activity relationship of HIV-1 protease inhibitors containing alpha-hydroxy-beta-amino acids. Detailed study of P1 site.
    Takashiro E; Hayakawa I; Nitta T; Kasuya A; Miyamoto S; Ozawa Y; Yagi R; Yamamoto I; Shibayama T; Nakagawa A; Yabe Y
    Bioorg Med Chem; 1999 Sep; 7(9):2063-72. PubMed ID: 10530956
    [TBL] [Abstract][Full Text] [Related]  

  • 11. L-735,524: the design of a potent and orally bioavailable HIV protease inhibitor.
    Dorsey BD; Levin RB; McDaniel SL; Vacca JP; Guare JP; Darke PL; Zugay JA; Emini EA; Schleif WA; Quintero JC
    J Med Chem; 1994 Oct; 37(21):3443-51. PubMed ID: 7932573
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Protein structure-based design of potent orally bioavailable, nonpeptide inhibitors of human immunodeficiency virus protease.
    Reich SH; Melnick M; Davies JF; Appelt K; Lewis KK; Fuhry MA; Pino M; Trippe AJ; Nguyen D; Dawson H
    Proc Natl Acad Sci U S A; 1995 Apr; 92(8):3298-302. PubMed ID: 7724556
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Synthesis and structure-activity relationships of a series of penicillin-derived HIV proteinase inhibitors containing a stereochemically unique peptide isostere.
    Holmes DS; Bethell RC; Cammack N; Clemens IR; Kitchin J; McMeekin P; Mo CL; Orr DC; Patel B; Paternoster IL
    J Med Chem; 1993 Oct; 36(21):3129-36. PubMed ID: 8230099
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inhibitors of HIV-1 proteinase containing 2-heterosubstituted 4-amino-3-hydroxy-5-phenylpentanoic acid: synthesis, enzyme inhibition, and antiviral activity.
    Scholz D; Billich A; Charpiot B; Ettmayer P; Lehr P; Rosenwirth B; Schreiner E; Gstach H
    J Med Chem; 1994 Sep; 37(19):3079-89. PubMed ID: 7932531
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Studies of HIV-1 protease inhibitors. I. Incorporation of a reduced peptide, simple aminoalcohol, and statine analog at the scissile site of substrate sequences.
    Sakurai M; Sugano M; Handa H; Komai T; Yagi R; Nishigaki T; Yabe Y
    Chem Pharm Bull (Tokyo); 1993 Aug; 41(8):1369-77. PubMed ID: 8403085
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Potent HIV protease inhibitors containing a novel (hydroxyethyl)amide isostere.
    Beaulieu PL; Wernic D; Abraham A; Anderson PC; Bogri T; Bousquet Y; Croteau G; Guse I; Lamarre D; Liard F; Paris W; Thibeault D; Pav S; Tong L
    J Med Chem; 1997 Jul; 40(14):2164-76. PubMed ID: 9216835
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Statine based tripeptides as potent inhibitors of HIV-1 replication.
    Fehrentz JA; Chomier B; Bignon E; Venaud S; Chermann JC; Nisato D
    Biochem Biophys Res Commun; 1992 Oct; 188(2):873-8. PubMed ID: 1445328
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A series of penicillin derived C2-symmetric inhibitors of HIV-1 proteinase: synthesis, mode of interaction, and structure-activity relationships.
    Humber DC; Bamford MJ; Bethell RC; Cammack N; Cobley K; Evans DN; Gray NM; Hann MM; Orr DC; Saunders J
    J Med Chem; 1993 Oct; 36(21):3120-8. PubMed ID: 8230098
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Configurations of diastereomeric hydroxyethylene isosteres strongly affect biological activities of a series of specific inhibitors of human-immunodeficiency-virus proteinase.
    Konvalinka J; Litera J; Weber J; Vondrásek J; Hradílek M; Soucek M; Pichová I; Majer P; Strop P; Sedlácek J; Heuser AM; Kottler H; Kräusslich HG
    Eur J Biochem; 1997 Dec; 250(2):559-66. PubMed ID: 9428710
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Structure-based design of novel HIV protease inhibitors: sulfonamide-containing 4-hydroxycoumarins and 4-hydroxy-2-pyrones as potent non-peptidic inhibitors.
    Thaisrivongs S; Janakiraman MN; Chong KT; Tomich PK; Dolak LA; Turner SR; Strohbach JW; Lynn JC; Horng MM; Hinshaw RR; Watenpaugh KD
    J Med Chem; 1996 Jun; 39(12):2400-10. PubMed ID: 8691434
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.